A multinational research team led by researchers at Institute of Science Tokyo, RIKEN, and the University of Toronto has revealed how a tryptophan-rich allosteric communication network regulates ...

A multinational research team led by researchers at Institute of Science Tokyo, RIKEN, and the University of Toronto has ...

Atrogi AB, a clinical stage biotech company pioneering novel GPCR pathway-signalling modulators to transform metabolic and muscle health, today announces that the first subjects have been dosed in a ...

First-in-class oral therapy ATR-258 mimics the effects of exercise - driving fat loss, increasing muscle, and improving metabolism - with broad potential as a novel treatment for muscle-sparing ...

New Assay Expands INDIGO’s GPCR Portfolio and Supports Development of Next-Generation CNS-Related Therapeutics STATE ...

First-in-class oral therapy mimics the effects of exercise with broad potential as a novel treatment for muscle-sparing weight loss ...

MONTREAL, March 19, 2026 /PRNewswire/ -- Congruence Therapeutics today announced that the first participant has been dosed in its Phase 1/1b clinical trial evaluating CGX-926, an oral small-molecule ...

Structure Therapeutics’ aleniglipron Phase 2 shows ~16% placebo-adjusted weight loss; a best-in-class oral GLP-1 with strong cash runway.

Placebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks with no evidence of weight loss plateau in ...

Vesicor Therapeutics, Inc., a San Gabriel, California-based early development stage biotechnology corporation focused on the development of p53-based cancer therapeutics delivered via ...

Vesicor Therapeutics, Inc., a San Gabriel, California-based early development stage biotechnology corporation focused on the development of p53-based ...